Why chemotherapy is not the main treatment for kidney cancer — and what is used instead

Because the commonest kidney cancer is naturally resistant to it. Kidney tubule cells exist to clear foreign chemicals out of the blood, and they carry drug-efflux pumps - the best known is P-glycoprotein, made by the MDR-1 gene - that push a wide range of molecules straight back out of the cell. Most kidney cancers start in those cells and keep that machinery, so a cytotoxic drug often leaves before it can act. Clear cell tumours also tend to have a smaller fraction of cells dividing at any one moment, and chemotherapy is designed to catch cells while they divide. This was tested over decades rather than assumed, and NCCN guidance reflects it: chemotherapy is not standard treatment for clear cell kidney cancer.

For the common clear cell type it rarely produces useful, lasting shrinkage, which is why it is not offered as routine treatment. That is a statement about one class of drug in one type of tumour, not about kidney cancer as a whole. Several rarer kidney cancers do respond to chemotherapy, and children's kidney cancer is treated with it as a matter of course. The honest summary is that chemotherapy has a narrow, specific role here instead of the central one it holds in many other cancers. If you have been told chemotherapy is not planned, ask which type your pathology report names, because the type is what decides the answer.

For disease still confined to the kidney, surgery to remove the tumour or the kidney is the main treatment, and it can be curative. For advanced or recurrent disease the two systemic classes are targeted therapy, usually a VEGF tyrosine kinase inhibitor taken as a tablet, and immunotherapy, given as an infusion, using a PD-1 inhibitor sometimes paired with a CTLA-4 inhibitor. Radiation delivered as SBRT is used for selected sites and for symptom control. At CION the systemic treatment, radiation, diagnosis and follow-up are delivered in-house by our medical oncology and radiation teams, while surgery, ablation and PET-CT are coordinated with specialist urology, uro-oncology and interventional radiology partners.

In a small number of specific situations. Collecting duct carcinoma and renal medullary carcinoma are rare kidney cancers that behave more like cancers of the urinary lining than like clear cell disease, and chemotherapy is used for them. Cancer of the renal pelvis starts in the lining inside the kidney rather than in its filtering tissue, so it is treated along urothelial lines, where chemotherapy does work. Wilms tumour, the childhood kidney cancer, is a different disease in which chemotherapy is a core part of curative treatment. It may also be considered case by case in aggressive disease where immune-based treatment is unsuitable or has stopped working. Your pathology report is what decides which of these applies.

No. There is no standard adjuvant chemotherapy after surgery for kidney cancer, so nothing is being withheld if none is offered. What is discussed after surgery depends on how much risk the pathology suggests. For most people that means a surveillance schedule of scans and blood tests over several years, because early recurrence found on a scan is far easier to act on. For selected people whose pathology puts them in a higher-risk group, adjuvant immunotherapy is discussed instead, and that decision is made at a tumour board rather than by one doctor. Ask what risk group your pathology places you in and what the follow-up schedule will be.

Kidney cancer has long been called radioresistant, and it is true that conventional radiotherapy given in many small daily doses does little to the primary tumour. Modern stereotactic radiotherapy, or SBRT, is a different proposition: it delivers a high dose very precisely in a handful of sessions, and kidney cancer does respond to that. It is used for deposits in bone or elsewhere, for pain and other symptoms, for selected single sites of spread, and sometimes for the kidney tumour itself when surgery is not an option. SBRT and other radiation are delivered in-house at CION. Whether it suits your situation depends on where the disease is and what else is planned.